Celebrity Cruises reveals what's new in 2027 and 2028
The Xcel, debuting this November, will be one of seven ships and three in the Edge class sailing in Europe in 2027 and 2028. Its Mediterranean sailings will range from seven to 12 nights.
Other Celebrity ships sailing in Europe will be the Ascent, Apex, Eclipse, Silhouette and Infinity. The Infinity will sail the region year-round for the first time and do off-season sailings to the Canary Islands and Morocco.
The Celebrity Millennium will homeport from Tokyo's Narita terminal for a second season with overnight stays in four Japanese cities.
In Alaska, the Edge's season will include more sailings at the beginning and end of the season than in previous years. Celebrity soon will reveal the start and end dates for the Edge's Alaska season at a later date.
The Celebrity Solstice and the Celebrity Summit will also return to Alaska.
The Europe and Japan cruises are on sale; Alaska cruises go on sale Sept. 9.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
15 minutes ago
- Yahoo
ATARI: Capital increase in relation to the repayment in shares of loans from IRATA LLC
Capital increase in relation to the repayment in shares of loans from IRATA LLC PARIS, FRANCE (August 7, 2025 - 6.00 pm CET) - Atari® (Euronext Growth Paris: ALATA) — one of the world's most iconic consumer brands and interactive entertainment producers — today announces the repayment of€13.9 million loans previously granted to Atari SA by Irata LLC, the holding company of Wade Rosen, Chairman and Chief Executive Officer of Atari SA, through a capital increase reserved to IRATA LLC. The repayment in Atari SA new shares and the reserved capital increase have been approved unanimously by the Board of Directors1 of Atari, SA pursuant to the authorization granted by the shareholders meeting held on September 24, 2024 (Resolution 12). The loans which are repaid, had been granted on January 31, 2024, March 4, 2024, April 10, 2024, July 22,2024, July 31, 2024, January 3, 2025 and January 31, 2025 for a total amount (principal and interest) of €13.9 million and bearing an annual interest of 10%. Upon repayment of the loans, 97,718,187 new shares (representing 21% of Atari, SA share capital) will be issued with no discount on the share price2 and will be admitted to trading. As a result, the total number of outstanding shares will be 559,082,939. Following this capital increase, IRATA LLC will hold 41.7% of the share capital and 39.5% of the voting rights3. After this repayment, the outstanding amount of loans granted by IRATA LLC to Atari, SA and its subsidiaries represent approximately €10M in principal amount. Breakdown of capital, before capital increase Ownership June 30, 2025 Number ofshares % Theoreticalvoting rights % Exercisablevoting rights % Irata LLC 135,379,861 29.3% 135,979,861 27.3% 135,979,861 27.5% Stephen Kick 31,463,004 6.8% 62,926,008 12.6% 62,926,008 12.7% Mr Alexandre Zyngier 3,779,778 0.8% 4,830,807 1.0% 4,830,807 1.0% Treasury shares 3,253,426 0.7% 3,253,426 0.7% 0 0.0% Public 287,488,683 62.3% 290,559,871 58.4% 290,559,871 58.8% Total 461,364,752 100.0% 497,549,973 100.0% 494,296,547 100.0% Breakdown of capital, after capital increase Ownership Post capital increase Number ofshares % Theoreticalvoting rights % Exercisablevoting rights % Irata LLC 233,098,048 41.7% 233,698,048 39.3% 233,698,048 39.5% Stephen Kick 31,463,004 5.6% 62,926,008 10.6% 62,926,008 10.6% Mr Alexandre Zyngier 3,779,778 0.7% 4,830,807 0.8% 4,830,807 0.8% Treasury shares 3,253,426 0.6% 3,253,426 0.5% 0 0.0% Public 287,488,683 51.4% 290,559,871 48.8% 290,559,871 49.1% Total 559,082,939 100.0% 595,268,160 100.0% 592,014,734 100.0% 1 Mr Wade Rosen abstained from participating in the decision of the Board of Directors2 New Atari shares issued on the basis of a 3-day VWAP as of 31 July 2025 of €0.14503 In addition, IRATA LLC holds 195,163,398 convertible bondsAbout ATARI Atari is an interactive entertainment company and an iconic gaming industry brand that transcends generations and audiences. The company is globally recognized for its multi-platform, interactive entertainment and licensed products. Atari owns and/or manages a portfolio of more than 400 unique games and franchises, including world-renowned brands like Asteroids®, Centipede®, Missile Command®, Pong®, and RollerCoaster Tycoon®. Atari has offices in New York and Paris. Visit us online at Atari shares are listed in France on Euronext Growth Paris (ISIN Code FR0010478248, Ticker ALATA) and OTC Pink Current (Ticker PONGF). ©2025 Atari Interactive, Inc. Atari wordmark and logo are trademarks owned by Atari Interactive, Inc. Contacts Atari - Investor RelationsTel +33 1 83 64 61 57 - investisseur@ | Actus finance & communication - Marie Calleux Tel +33 1 53 65 68 68 – atari@ Listing Sponsor - Euroland CorporateTel +33 1 44 70 20 84 - Julia Bridger - jbridger@ DISCLAIMER This press release contains certain non-factual elements, including but not restricted to certain statements concerning its future results and other future events. These statements are based on the current vision and assumptions of Atari's leadership team. They include various known and unknown uncertainties and risks that could result in material differences in relation to the expected results, profitability and events. In addition, Atari, its shareholders and its respective affiliates, directors, executives, advisors and employees have not checked the accuracy of and make no representations or warranties concerning the statistical or forward-looking information contained in this press release that is taken from or derived from third-party sources or industry publications. If applicable, these statistical data and forward-looking information are used in this press release exclusively for information. Attachment ATARI_PR-Loan-repayment_20250807Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Fast Company
16 minutes ago
- Fast Company
Sources reveal the Trump administration's plans for cutting U.S. drug prices
The Trump administration has been talking to drugmakers about ways to raise prices of medicines in Europe and elsewhere in order to cut drug costs in the United States, according to a White House official and three pharmaceutical industry sources. U.S. officials told drug companies it would support their international negotiations with governments if they adopt 'most favored nation' pricing under which U.S. drug costs match the lower rates offered to other wealthy countries, the White House official said. The U.S. is currently negotiating bilateral trade deals and setting tariff rates on the sector. The Trump administration has asked some companies for ideas on raising prices abroad, two of the sources said, describing multiple meetings over several months aimed at lowering U.S. prices without triggering cuts to research and development spending drugmakers insist would result. The White House official called the effort collaborative, saying both sides were seeking advice from each other. The U.S. pays more for prescription drugs than any other country, often nearly three times as much as other developed nations. President Donald Trump has repeatedly said he wants to narrow this gap to stop Americans from being 'ripped off.' The previously unreported discussions reflect the challenges Trump faces to achieve that goal, and are the backdrop to the letters he sent last week to CEOs of 17 major drugmakers, urging them to cut U.S. prices to match those paid overseas. Unlike in the U.S., where market forces determine drug prices, European governments typically negotiate directly with companies to set prices for their national healthcare systems. Anna Kaltenboeck, a health economist at Verdant Research, said European nations have leverage to drive pricing and are sometimes willing to walk away from purchasing medicines they deem too expensive. Drugmakers generate most of their sales in the U.S. The Pharmaceutical Research and Manufacturers of America — the industry's main lobby group — has always argued that cutting U.S. prices would stifle innovation by lowering R&D spending. PhRMA declined to comment on the private meetings. Kaltenboeck said past studies had shown that drugmakers made enough money in the U.S. to more than fund their entire global R&D spends. 'Prices can come down in the United States without being increased in other countries, and we can still get innovation,' she said. TOP PRIORITY Despite the Trump administration's tariff threats and pressure to move more manufacturing to the U.S., the push to raise European drug prices is its top priority in discussions with industry, according to a senior executive at a European drugmaker, who spoke on condition of anonymity about the confidential meetings. 'This is the key conversation right now with PhRMA and every company getting that message from Pennsylvania Avenue to a point that we are already executing on it,' the executive said, referring to the White House address. The company had already met with European governments on the issue, the executive added. An E.U. Commission spokesperson said it is in regular contact with the pharma industry and pointed to an agreement with the U.S. that should it impose tariffs on pharmaceuticals, they would be capped at 15%. When asked how the administration would support international drug price negotiations, the White House official referred Reuters to Trump's most favored nation executive order from May. That order directed trade officials to pursue trade and legal action against countries keeping drug prices below fair market value. In last week's letters, Trump complained that since the May executive order, most industry proposals had simply shifted blame for high prices or requested policy changes that would result in billions in industry handouts. A second source, a pharmaceutical executive who was not authorized to speak on the matter, said the Trump administration has been continually meeting with representatives of his company and had discussed strategies for raising drug prices internationally. 'There's a big push from the administration to drive up prices outside the U.S.,' the executive said. The executive said the Trump administration had been looking at using trade talks with the UK and EU as leverage, and considered pressuring countries to spend a higher percentage of GDP on new medicines or offering tariff breaks in exchange for higher drug spending. It was understood that the UK deal specifically aims to get the country to ramp up investment in branded medicines over time, the executive said. A spokesperson for the UK government said it would continue to work closely with the U.S. and its own pharmaceutical industry to understand the possible impact of any changes to drug pricing, without commenting on the trade talks. In April, over 30 industry CEOs including those from AstraZeneca, Bayer and Novo Nordisk signed a letter to European Union President Ursula von der Leyen saying Europe needed to rethink its pricing policies. 'It's going to be very difficult for a country that already has the ability to control what it spends to go in the other direction,' Kaltenboeck said, 'and it doesn't make much sense for them politically.'
Associated Press
18 minutes ago
- Associated Press
Helping Beverage Companies Navigate the EUDR: Beverage Industry Environmental Roundtable (BIER) Releases Sector-Specific Interpretation Guide
August 7, 2025 /3BL/ - The Beverage Industry Environmental Roundtable (BIER) has released the Beverage Industry EUDR Interpretation Guide, a practical, sector-specific resource designed to help beverage companies understand and meet the requirements of the European Union Deforestation Regulation (EUDR) (EU 2023/1115). Effective June 29, 2023, the EUDR introduced strict due diligence requirements for companies placing cattle, coffee, cocoa, soy, palm oil, rubber, or wood - or products derived from them - on the EU market or exporting them from it. For the beverage industry, this regulation is highly relevant as it covers both raw ingredients (like coffee, cocoa, and palm derivatives) and select wood-based packaging (such as barrels and branded wooden crates). Full compliance for large and medium-sized operators begins December 30, 2025, with Small and Medium-sized Enterprises (SMEs) following by June 30, 2026. The guide is designed for beverage manufacturers, brand owners, and procurement and sustainability teams who need clear, actionable direction on how to implement EUDR compliance across their supply chains. It provides: By providing a beverage-focused lens on a complex regulation, the guide empowers companies to reduce compliance risk, maintain market access, and build robust, future-proof sustainability practices. 'The EUDR presents both a challenge and an opportunity for the beverage sector. Our members needed clear, actionable guidance on how to navigate this complex regulation, and that's exactly what this guide delivers, helping companies meet their obligations while advancing environmental stewardship.' ~ Erica Pann, Executive Director of BIER. The Beverage Industry EUDR Interpretation Guide reinforces BIER's mission to accelerate environmental progress in the beverage sector by turning complex sustainability challenges into actionable solutions. The Beverage Industry EUDR Interpretation Guide is available for download at For more information, please contact: Erica Pann, BIER Executive Director [email protected] About BIERBIER is a technical coalition of leading global beverage companies working together to advance environmental sustainability within the beverage sector. Formed in 2006, BIER is a common voice across the beverage sector, speaking to influence global standards on environmental sustainability aspects most relevant to the sector, affect change both up and down the supply chain, and share best practices that raise the bar for environmental performance of the industry. By doing so, BIER is able to monitor data and trends, engage with key stakeholders, develop best practices, and guide a course of action for the future. BIER members include Anheuser-Busch InBev, Asahi Group Holdings, Bacardi, Brown-Forman, Carlsberg Group, The Coca-Cola Company, Constellation Brands, Diageo, Heineken, Keurig Dr Pepper, LION, Molson Coors, Monster Energy, Ocean Spray Cranberries, PepsiCo, Pernod Ricard and Suntory Global Spirits. For more information, visit Visit 3BL Media to see more multimedia and stories from Beverage Industry Environmental Roundtable
